KRAS and non-small cell lung carcinoma: Three of these KRAS mutations (G12D, G13D, Q61H) are reported to confer either primary resistance, or to occur as “on-target” secondary mutations causing acquired resistance, to inhibitors of the most common KRAS mutation in NSCLC, which is KRAS G12C (70–72).